D.E. Shaw & Co’s Juno Therapeutics, Inc. JUNO Stock Holding History

D.E. Shaw & Co’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-288,927	Closed	-$13.2M	–	3953
2017 Q4	$13.2M	Sell	288,927 -667,597	-70%	-$33.3M	0.02%	875
2017 Q3	$42.9M	Buy	956,524 +915,730	+2,245%	+$31.2M	0.07%	356
2017 Q2	$1.22M	Buy	40,794 +22,998	+129%	+$567K	﹤0.01%	2290
2017 Q1	$395K	Buy	+17,796	New	+$382K	﹤0.01%	2847
2016 Q4	–	Sell	-28,045	Closed	-$686K	–	3715
2016 Q3	$842K	Buy	28,045 +15,563	+125%	+$484K	﹤0.01%	2502
2016 Q2	$480K	Sell	12,482 -2,287	-15%	-$94.9K	﹤0.01%	2814
2016 Q1	$563K	Sell	14,769 -4,317	-23%	-$150K	﹤0.01%	2720
2015 Q4	$839K	Sell	19,086 -8,347	-30%	-$414K	﹤0.01%	2775
2015 Q3	$1.12M	Buy	+27,433	New	+$1.2M	﹤0.01%	2523
2015 Q2	–	Sell	-3,484	Closed	-$211K	–	3981
2015 Q1	$211K	Buy	+3,484	New	+$169K	﹤0.01%	3436

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

D.E. Shaw & Co's JUNO Position: Q1 2018 in Review

D.E. Shaw & Co sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 288,927 shares — an estimated $13.2M sold.

D.E. Shaw & Co first reported a position in JUNO in Q1 2015 and held it in 10 quarters. The position peaked at $42.9M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

D.E. Shaw & Co reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
D.E. Shaw & Co sold 288,927 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $13.2M.
D.E. Shaw & Co first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 10 quarters.
D.E. Shaw & Co's Juno Therapeutics, Inc. position peaked at $42.9M in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on D.E. Shaw & Co's 13F filing for Q1 2018, filed 15 May 2018.